Abstract 225P
Background
Common evolution of non-muscle invasive bladder cancer (NMIBC) is local recurrence or progression to muscle invasive bladder cancer (MIBC). Some patients (pts) with NMIBC might develop metastases without progression to MIBC. Clinical evolution of these atypical presentations is unknown. Bladder cancer over the last 5 years has surged by over 13% in India. 50-70% of NMIBC cases recur, and around 10-20% progress to MIBC. Challenge in treatment is identifying the patients with mutations or gene expression patterns for targeted therapy, which is not feasible for all owing to high cost. While omics categorized Western patients, molecular landscape of Indian NMIBC remains incomplete. Herein we report a potential predictive signature, derived by combining transcriptome and whole exome sequencing data of a cohort of NMIBC patients treated in our centre.
Methods
From 2018 to 2021, 25 pts treated at our centre were included for the study, which has been approved by Institutional Ethics committee. Median age at diagnosis was 64Y. 88% received intravesical BCG. 60% were T1 stage and recurrence rate 48%. RNA sequencing and whole exome sequencing were performed on 25 primary NMBIC tumors. Machine learning model was used to predict recurrence status. Mutational status between recurrent and non-recurrent patients was also obtained. The gene expression signature was validated in external datasets including GSE13507 and GSE154261.
Results
435 genes were differentially expressed between recurred and non-recurred patients (p<0.05). Machine learning model predicted recurrence with 90% accuracy. Top pathways upregulated include signalling by nuclear receptors, Shigellosis etc. Downregulated include cell adhesion, PIK-AKT, and ECM reorganization. Validation in external dataset correlated positively with p<0.05. In addition to most previously reported signatures and APOBEC, we also found mutations in FGFR3, ABC transporters, and DAMP, differentially regulated between recurred vs non recurred patients.
Conclusions
We identified novel differentially regulated genes and mutations in genes that predicts recurrence with 90% accuracy. Further analysis in a larger set is underway to complete the validation of the predictive model.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sri Shankara Cancer Hospital and Research Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract